The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

In this latest version of Thematic Insights from The Market Online, we’re taking a break from mining and battery science to look at the healthcare sector once again.

This time around, we’re looking at the ASX-listed pharmaceutical space.

Our readers wanted to know what it takes for a company to list a new drug in the Australian market – a complicated process.

To that end, this report looks at what companies must do under the Australian drug regulator to bring a new product to pharmacy or supermarket shelves.

Our domestic regulator is the Therapeutic Goods Administration (TGA) – think of it as the lesser known cousin to the US Food and Drug Administration (FDA).

This report describes the TGA-regulated clinical trial process, ethics and legal considerations companies must satisfy, and other steps on the path to final approval.

Finally, this article looks at a number of companies in the space who are progressing medical technologies in Australia under the TGA regime.

What this report is designed to afford the reader an understanding of the ins-and-outs of the Australian pharmaceutical regulatory landscape.

Click here to read the latest Thematic Insights.

More From The Market Online

D3 Energy ready for key tests as second well hits target in South Africa

D3 Energy ready for key tests after drilling successfully reaches total depth in the second of…
The Market Online Video

ASX Today: Mideast jitters & earnings shake Friday’s optimism, but RBA set to hold

Greetings and welcome to HotCopper’s the ASX Today for Monday, kicking off Week 33 of the year, I’m Jon Davidson and last week’s

Stavely Minerals unveils robust Thursday’s gossan scoping study

Stavely Minerals has completed a robust Scoping Study on potential production from the Thursday’s deposits at…